TCRT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
TCRT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Alaunos Therapeutics's quarterly cash, cash equivalents, marketable securities declined from Mar. 2024 ($4.15 Mil) to Jun. 2024 ($2.46 Mil) but then stayed the same from Jun. 2024 ($2.46 Mil) to Sep. 2024 ($1.68 Mil).
Alaunos Therapeutics's annual cash, cash equivalents, marketable securities declined from Dec. 2021 ($76.05 Mil) to Dec. 2022 ($39.06 Mil) and declined from Dec. 2022 ($39.06 Mil) to Dec. 2023 ($6.06 Mil).
The historical data trend for Alaunos Therapeutics's Cash, Cash Equivalents, Marketable Securities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alaunos Therapeutics Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Cash, Cash Equivalents, Marketable Securities | Get a 7-Day Free Trial | 79.74 | 115.07 | 76.05 | 39.06 | 6.06 |
Alaunos Therapeutics Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Cash, Cash Equivalents, Marketable Securities | Get a 7-Day Free Trial | 11.94 | 6.06 | 4.15 | 2.46 | 1.68 |
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.
Alaunos Therapeutics (NAS:TCRT) Cash, Cash Equivalents, Marketable Securities Explanation
Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Thank you for viewing the detailed overview of Alaunos Therapeutics's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.
Boyle Kevin S. Sr. | director, officer: Chief Executive Officer | C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129 |
Robert Hofmeister | director | C/O TCR2 THERAPEUTICS INC., 100 BINNEY STREET, CAMBRIDGE MA 02142 |
Jaime Vieser | director | ONE FIRST AVENUE, PARRIS BUILDING 34, NAVY YARD PLAZA, BOSTON MA 02129 |
Robert W Postma | director | 141 MECOX ROAD, WATER MILL NY 11976 |
Michael Wong | officer: VP, Finance | C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BUILDING #34, BOSTON MA 02129 |
Abhishek K Srivastava | officer: See Remarks | C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054 |
Holger Weis | director | C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129 |
Christopher Bowden | director | 38 SIDNEY STREET, 2ND FLOOR, CAMBRIDGE MA 02139 |
Mary Thistle | director | C/O VIACELL, INC., 245 FIRST STREET, CAMBRIDGE MA 02142 |
James Huang | director | 9620 MEDICAL CENTER DRIVE, SUITE 300, ROCKVILLE MD 20850 |
Drew Deniger | officer: VP, Research & Development | C/O ALAUNOS THERAPEUTICS, INC., 8030 EL RIO ST., HOUSTON TX 77054 |
Groot Eleanor De | officer: EVP, Operations | C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129 |
Melinda Lackey | officer: Senior Vice President, Legal | C/O ZIOPHARM ONCOLOGY INC., 8030 EL RIO ST, HOUSTON TX 77054 |
Heidi Hagen | director | AASTROM BIOSCIENCES, INC., 24 FRANK LLOYD WRIGHT DRIVE, ANN ARBOR MI 48105 |
Raffaele Baffa | officer: Chief Medical Officer | C/O ZIOPHARM ONCOLOGY, INC., ONE FIRST AVENUE, PARRIS BLDG 34, BOSTON MA 02129 |
From GuruFocus
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
By GuruFocus Research • 02-09-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.